Skip to main content

Xavier Montalban Gairín

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

Xavier Montalban Gairín

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

I obtained my MD (1983) and PhD (1990) from UAB, and I completed my postgraduate fellowship at St. Thomas' Hospital and the National Hospital for Neurology and Neurosurgery in London. I obtained a Diploma in Comprehensive of Healthcare Institutions Management from ESADE (2005).

In addition to the positions I currently hold, between 2017 and 2020 I served as Professor of Medicine and Director of the Division of Neurology at the University of Toronto and as Director of the MS Center at St Michael's Hospital in the same city.

Since January 2023 I am the chair of the International Advisory Committee on Clinical Trials in Multiple Sclerosis sponsored by ECTRIMS and the National Multiple Sclerosis Society (NMSS), one of the most influential Committee in MS worldwide.

Regarding other leadership roles I am past President (2014-2016) and current Honorary Member of the Council of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). I’m also Board Member of the European Charcot Foundation, as well as serving on numerous local, national and international boards and committees.

My scientific production acrues over 800 scientific papers published in peer-reviewed journals, amounting? more than 52,000 citations and a Scopus H-Index of 101. Over the last consecutive five years I have ranked among the Clarivate most cited researchers.

I have been the Principal Investigator (PI) or Collaborator in more than 35 competitive Projects and have participated as PI in more than 150 clinical trials.

Of Note, I am the recipient of the 2022 John Dystel Prize for MS Research, awarded jointly by the National Multiple Sclerosis Society (NMSS) and the American Academy of Neurology (AAN). I’m the winner of the 2023 Charcot Award granted by the Multiple Sclerosis International Federation (MSIF), which recognises a lifetime of achievement in outstanding research into understanding and treating MS.

Projects

No disponible

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Multiple Sclerosis International Federation (MSIF)
Funding: 4737.51
Reference: MS_MSIF-MCDO2012
Duration: 07/01/2013 - 31/12/2015

Biological markers for rationalizing treatment decisions in Multiple Sclerosis (BEST-MS) Grand Agreement nº 305477

IP: Manuel Comabella Lopez
Collaborators: Sunny Malhotra Sareen, Jordi Rio Izquierdo, Xavier Montalban Gairín
Funding agency: EUROPEAN COMMISSION
Funding: 424320
Reference: BEST-MS_FP7HEALTH2012
Duration: 01/11/2012 - 31/10/2016

Red Española de Esclerosis Múltiple

IP: Xavier Montalban Gairín
Collaborators: Susana Otero Romero, Carlos Nos Llopis, Sunny Malhotra Sareen, Jaume Sastre Garriga, Jordi Rio Izquierdo, Fco. Javier Aymerich Martínez, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Silvia Soler García, Carmen Tur Gomez, Cristina Auger Acosta, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Alex Rovira Cañellas, Mar Tintore Subirana, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo
Funding agency: Instituto de Salud Carlos III
Funding: 198090
Reference: RD12/0032/0017
Duration: 01/01/2013 - 31/12/2016

Immunogenicity: assesing the clinical relevance and risk minimization of antibodies to biopharmaceuticals. IMI Grant Agreement nº 115303

IP: Manuel Comabella Lopez
Collaborators: Carmen Tur Gomez, Xavier Montalban Gairín, Nicolás Miguel Fissolo
Funding agency: The Innovative Medicines Initiative
Funding: 464328
Reference: ABIRISK_IMI2010
Duration: 01/03/2012 - 27/02/2018

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Navajo Garrido, Rafael José

Navajo Garrido, Rafael José

Director/a d'Àrea
Business Development Area
Read more
Perez Garcia, Lidia

Perez Garcia, Lidia

Administration and Management
Read more
Jose Luis Poza  Barrasus

Jose Luis Poza Barrasus

Biomedical Research in Gynaecology
Read more
Jerez  Cayuela, Andrés

Jerez Cayuela, Andrés

Main researcher
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.